Introduction
Real-world data suggest that women of childbearing age (WCBA) with inflammatory bowel disease are less likely than men of similar age to receive advanced therapies (ATs).1 This discrepancy may stem from concerns about potential future family planning. However, as the severity of disease and responses to ATs are expected to be similar between men and women, treatment should focus on disease control. This post hoc analysis aims to evaluate the efficacy, safety, and baseline demographics (including disease severity) in WCBA and in men of similar age treated with upadacitinib (UPA), supporting the need to prioritize disease control equally in both groups.
Aims & Methods
This post hoc analysis evaluated the efficacy and safety of UPA in WCBA (18-49 years [yrs]) and men of similar age in UC (U-ACCOMPLISH, U-ACHIEVE) or CD (U-EXCEL, U-EXCEED, U-ENDURE) phase 3 trials. Patients were randomized 2:1 to receive once-daily (QD) UPA 45 mg (UPA45) or placebo (PBO) induction therapy for 8 (ulcerative colitis [UC] trials) or 12 weeks (wks; Crohn's disease [CD] trials); responders to UPA induction therapy were rerandomized (1:1:1) to PBO, UPA 15 mg, or UPA 30 mg QD for 52 wks of maintenance.2,3 WCBA were required to use a protocol-defined method of birth control from baseline to ≥ 30 days after the last dose of the study drug. Efficacy was assessed for UC (clinical remission [CR] per Adapted Mayo Score, endoscopic improvement, endoscopic remission, histologic-endoscopic mucosal improvement) or CD (CR per Crohn’s Disease Activity Index or Stool Frequency/Abdominal Pain Score, endoscopic response, endoscopic remission) at induction wk 8/12 and maintenance wk 52. Safety was evaluated through maintenance wk 52.
Results
This analysis included female (42.2%) and male patients (57.8%) aged 18-49 yrs with UC or CD (N=1424). Among UPA45-treated patients, mean disease duration was numerically higher in WCBA than in men (UC: 7.5 vs 6.6 yrs; CD: 9.2 vs 8.7 yrs). Among UPA45-treated patients with CD, a numerically higher proportion of WCBA had previously failed multiple biologics (≥2) compared with men (66.1% vs 56.5%), whereas rates were comparable in UC. At induction wk 8/12 and maintenance wk 52, both UPA-treated WCBA and men achieved numerically higher efficacy rates than PBO-treated patients across all clinical and endoscopic endpoints for UC and CD (Table). The rates among WCBA were numerically similar to those among men of similar age, with overlapping confidence intervals. Efficacy rates for men and women were consistent with the overall study population, as previously reported.4,5 Overall treatment-emergent adverse events were slightly higher for WCBA compared with men with UC or CD at induction wk 8 and maintenance wk 52.
| Endpointa | 18-49 yrs | Wk 8/12 of Induction | Wk 52 of Maintenanceb |
PBO (n/N) % | UPA 45 mg QD (n/N) % | PBO (n/N) % | UPA 15 mg QD (n/N) % | UPA 30 mg QD (n/N) % |
Patients with UC Clinical remission per AMSc
Endoscopic improvementd
Endoscopic remissione
HEMIf
|
Women Men
Women Men
Women Men Women Men |
(2/81) 2.5 (9/133) 7.1
(6/81) 7.4 (12/133) 8.8
(2/81) 2.5 (2/133) 1.6
(4/81) 4.9 (10/133) 7.6 |
(68/172) 39.5 (66/258) 25.5
(85/172) 49.4 (92/258) 35.5
(33/172) 19.2 (41/258) 16.0
(72/172) 41.9 (78/258) 30.4 |
(8/61) 13.1 (6/77) 8.0
(9/61) 15.1 (9/77) 12.0
(4/61) 6.6 (5/77) 6.9
(9/61) 14.9 (7/77) 9.6 |
(23/59) 38.5 (38/100) 38.0
(27/59) 45.3 (49/100) 48.5
(14/59) 24.1 (25/100) 25.1
(25/59) 41.9 (37/100) 37.2 |
(43/71) 60.8 (40/88) 45.0
(49/71) 69.0 (47/88) 53.9
(25/71) 34.8 (20/88) 22.2
(44/71) 61.8 (44/88) 49.7 |
| Overall TEAEsg | 18-49 yrs Women Men | PBO (n/N) % (47/82) 57.7 (54/135) 40.4 | UPA 45 mg QD (n/N) % (109/173) 63.0 (127/260) 48.8 | PBOh E (E/100 PYs) 198 (533.7) 150 (357.8] | UPA 15 mg QDi E (E/100 PYs) 156 (324.1) 229 (286.1) | UPA 30 mg QDj E (E/100 PYs) 196 (307.9) 181 (240.3) |
Patients with CD Clinical remission per CDAIk
Clinical remission per SF/APSl
Endoscopic responsem
Endoscopic remissionn |
Women Men
Women Men
Women Men
Women Men
|
(29/119) 24.4 (35/156) 22.6
(19/119) 16.0 (30/156) 19.2
(11/119) 9.2 (11/156) 7.1
(6/119) 5.0 (8/156) 5.1 |
(105/229) 46.0 (134/276) 48.7
(104/229) 45.4 (152/276) 55.1
(94/229) 41.2 (128/276) 46.4
(64/229) 28.0 (69/276) 25.0 |
(15/84) 17.9 (9/87) 10.3
(12/84) 14.3 (11/87) 12.6
(5/84) 6.0 (6/87) 6.9
(3/84) 3.7 (5/87) 5.7 |
(26/65) 40.0 (38/113) 33.6
(23/65) 35.4 (35/113) 31.0
(18/65) 27.0 (29/113) 25.6
(12/65) 18.6 (18/113) 16.0 |
(41/79) 51.9 (62/106) 58.5
(37/79) 46.8 (62/106) 58.5
(34/79) 43.4 (49/106) 46.2
(28/79) 35.5 (33/106) 31.1 |
| Overall TEAEsg | 18-49 yrs Women Men
| PBO (n/N) % (82/119) 68.9 (91/156) 57.8
| UPA 45 mg QD (n/N) % (170/229) 74.2 (165/276) 60.0
| PBOo E (E/100 PYs) 201 (504.4) 182 (462.3)
| UPA 15 mg QDp E (E/100 PYs) 157 (364.1) 270 (344.5)
| UPA 30 mg QDq E (E/100 PYs) 205 (337.8) 255 (300.5)
|
Table. Efficacy and Safety of Upadacitinib in Women of Childbearing Age Versus Men of Comparable Age With Moderate to Severe UC or CD AMS, Adapted Mayo Score; APS, abdominal pain score; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; COVID-19, coronavirus disease 2019; E, event; ES, endoscopic subscore; HEMI, histological endoscopic mucosal improvement; NRI-C, nonresponder imputation-coronavirus disease 2019; PBO, placebo; PY, patient-year; QD, once daily; RBS, rectal bleeding score; SES-CD, simple endoscopic disease score for Crohn’s disease; SF, stool frequency; SF/APS, stool frequency/abdominal pain score; TEAE, treatment-emergent adverse event; UC, ulcerative colitis; UPA, upadacitinib; wk, week; yrs, years. aEfficacy data were analyzed using NRI-C, defined as nonresponder imputation incorporating multiple imputations to handle missing data due to COVID-19. Patients were considered nonresponders for binary endpoints at and after the UC/CD-related corticosteroid censoring time point through the end of the induction period studied. No statistical comparisons were made. bIncludes all patients who responded to 8- or 12-wk UPA 45 mg QD induction treatment and were enrolled under the protocol for 52-wk maintenance treatment period in cohort 1. cAMS ≤ 2, with SFS ≤ 1 and not greater than baseline, RBS = 0, and ES ≤ 1. dES ≤ 1. eES = 0. fES of ≤ 1 and Geboes score ≤ 3.1. gTEAEs are defined as events that begin either on or after the first dose of the study drug in either maintenance study (U-ACHIEVE/U-ENDURE) and within 30 days after the last dose administration of the study drug for patients who do not participate in either LTE (U-ACTIVATE/U-ENDURE) or until the first dose of the study drug in the LTE. hWomen: n = 62, PYs = 35.7; men: n = 77, PYs = 42.7; iWomen, n = 59, PYs = 46.7; men, n = 102, PYs = 79.9; jWomen, n = 71, PYs = 63.0; men, n = 88, PYs = 75.3; kCDAI < 150. lAverage daily very soft or liquid SF ≤ 2.8 and average daily APS ≤ 1.0 and both not greater than baseline. mSES-CD > 50% from baseline of the induction study (or for patients with an SES-CD of 4 at baseline of the induction study, at least a 2-point reduction from baseline), as scored by the central reviewer. nSES-CD ≤ 4 and at least 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer. oWomen: n = 84, PYs = 39.8; men: n = 87, PYs = 39.4; pWomen, n = 65, PYs = 43.1; men: n = 113, PYs = 78.4; qWomen, n = 79, PYs = 60.7; men: n = 106, PYs = 84.9. |
Conclusion
UPA-treated WCBA with UC or CD achieved clinical and endoscopic outcomes comparable to those of men of similar age, despite some differences in disease duration. Safety profiles aligned with previous UPA clinical trials. Physicians should prioritize disease control in both populations while incorporating family planning discussions with their patients.
References
- Mahadevan U, et al. Am J Gastroenterol. 2025;120(12S):S15-16. [Abstract].
- Danese S, et al. Lancet. 2022;399:2113–284.
- Loftus EV and Panes J, et al. N Engl J Med 2023;388:1966-80.
Disclosure
Funding: AbbVie funded these studies (NCT03345849, NCT03345836, NCT03345823, NCT02819635, and NCT03653026) and participated in the study design, research, analysis, data collection and interpretation, review, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.
Acknowledgments: AbbVie and the authors thank the participants, study sites, and investigators who participated in this clinical trial. Paulette Krishack, PhD, of AbbVie, provided medical writing support; Angela T. Hadsell and Catherine Barone, PhD, of AbbVie, provided editorial support.
Uma Mahadevan has acted as a consultant for AbbVie, Bristol Myers Squibb, Gilead, Janssen, Pfizer, and Takeda.
Jamie Kinnucan is an advisory board member and consultant for AbbVie, Pfizer, Takeda, Johnson & Johnson, and Eli Lilly.
Marla Dubinsky consults for AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Gilead Sciences, Janssen Pharmaceuticals, Pfizer, Prometheus Labs, Sanofi, Shire, and Takeda and receives research grants from AbbVie and Janssen Pharmaceuticals.
Sina Ogholikhan, Leah Rizzo, Elena Dubcenco, Tafadzwa Kasambira, and Andrew Garrison are employees of AbbVie and may own stock and/or stock options.
Remo Panaccione has received consulting fees, speaker fees, and research support from Abbott, AbbVie, Abivax, Alimentiv, Amgen, AnaptysBio, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pendopharm, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Sanofi, Satisfai Health, Sublimity Therapeutics, Takeda, Theravance Biopharma, Trellus, UCB, Ventyx, and Viatris.